E-viri
Recenzirano
Odprti dostop
-
Tini, Elvira; Smigielski, Lukasz; Romanos, Marcel; Wewetzer, Christoph; Karwautz, Andreas; Reitzle, Karl; Correll, Christoph U.; Plener, Paul L.; Malzahn, Uwe; Heuschmann, Peter; Unterecker, Stefan; Scherf-Clavel, Maike; Rock, Hans; Antony, Gisela; Briegel, Wolfgang; Fleischhaker, Christian; Banaschewski, Tobias; Hellenschmidt, Tobias; Imgart, Hartmut; Kaess, Michael; Kölch, Michael; Renner, Tobias; Reuter-Dang, Su-Yin; Rexroth, Christian; Schulte-Körne, Gerd; Theisen, Frank; Fekete, Stefanie; Taurines, Regina; Gerlach, Manfred; Egberts, Karin Maria; Walitza, Susanne
Comprehensive psychiatry, 20/May , Letnik: 115Journal Article
Sertraline is a selective serotonin reuptake inhibitor with specific indications in child and adolescent psychiatry. Notwithstanding its frequent use and clinical benefits, the relationship between pharmacokinetics, pharmacodynamics, efficacy, and tolerability of sertraline across indications, particularly in non-adult patients, is not fully understood. This naturalistic therapeutic drug monitoring (TDM) study was conducted in a transdiagnostic sample of children and adolescents treated with sertraline (n = 78; mean age, 14.22 ± 2.39; range, 7–18 years) within the prospective multicenter “TDM-VIGIL” project. Associations between dose, serum concentration, and medication-specific therapeutic and side effects based on the Clinical Global Impression scale were examined. Tolerability was measured qualitatively with the 56-item Pediatric Adverse Event Rating Scale. A strong linear positive dose–serum concentration relationship (with dose explaining 45% of the variance in concentration) and significant effects of weight and co-medication were found. Neither dose nor serum concentration were associated with side effects. An overall mild-to-moderate tolerability profile of sertraline was observed. In contrast with the transdiagnostic analysis that did not indicate an effect of concentration, when split into depression (MDD) and obsessive-compulsive disorder (OCD) diagnoses, the probability of clinical improvement significantly increased as both dose and concentration increased for OCD, but not for MDD. This TDM–flexible-dose study revealed a significant diagnosis-specific effect between sertraline serum concentration and clinical efficacy for pediatric OCD. While TDM already guides clinical decision-making regarding compliance, dose calibration, and drug–drug interactions, combining TDM with other methods, such as pharmacogenetics, may facilitate a personalized medicine approach in psychiatry. •The dose-, concentration- and age-related effects of SSRIs are not well understood.•The study was conducted in patients aged 7–18 treated with sertraline (25–250 mg/day).•Dose explained 45% of the variance in serum drug concentration across indications.•Clinical improvement was associated with dose and concentration in OCD, but not MDD.•Therapeutic drug monitoring is a promising tool in OCD research and therapy.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.